Background: With the emergence of novel antibody-drug
conjugates, treatment decisions for patients with low and ultra-low HER2 expression have been transformed. However, the
epidemiological characteristics of the relatively rare male
breast cancer remain unclear. This study aims to explore the
clinicopathological and immunophenotypic characteristics of
male invasive breast cancer with low and ultra-low HER2
expression.
第一作者机构：[1]Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China
推荐引用方式(GB/T 7714)：
Shang Jiuyan,Miao Jiaxian,Niu Shuyao,et al.Redefining Therapeutic Landscapes: Clinicopathological Insights into Low and Ultra-Low HER2 Expression in Male Breast Cancer[J].LABORATORY INVESTIGATION.2025,105(3):doi:10.1016/j.labinv.2024.102451.
APA：
Shang, Jiuyan,Miao, Jiaxian,Niu, Shuyao,Sun, Xuemei&Liu, Yueping.(2025).Redefining Therapeutic Landscapes: Clinicopathological Insights into Low and Ultra-Low HER2 Expression in Male Breast Cancer.LABORATORY INVESTIGATION,105,(3)
MLA：
Shang, Jiuyan,et al."Redefining Therapeutic Landscapes: Clinicopathological Insights into Low and Ultra-Low HER2 Expression in Male Breast Cancer".LABORATORY INVESTIGATION 105..3(2025)
